SCHEMBL2382489

SCHEMBL2382489

COC(=O)CNC(=O)c1c(O)c2c(OC)cccc2n(C)c1=O

nearest known ligand 0.54

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 1/20 0.54
HIF1A Q16665 12/20 0.52
TSHR P16473 1/20 0.52
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
KDM4E B2RXH2 1/20 0.46
EGLN1 Q9GZT9 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12254514 0.91 HIF1A (0.52) HDAC4HIF1ATSHRMEN1KMT2A
SCHEMBL2383493 0.91 HIF1A (0.63) HIF1AEGLN1
SCHEMBL2383052 0.87 MEN1 (0.47) HIF1ATSHRMEN1KMT2ANPC1
SCHEMBL2383082 0.86 EGLN1 (0.48) HIF1ATSHRMEN1KMT2ANPC1
SCHEMBL2383780 0.86 HIF1A (0.52) HIF1AMEN1KMT2ANPC1RAB9A
SCHEMBL2385578 0.86 MEN1 (0.53) HIF1AMEN1KMT2ANPC1RAB9A
SCHEMBL2382763 0.84 HDAC4 (0.46) HDAC4HIF1ATSHRMEN1KMT2A
SCHEMBL2382224 0.83 HIF1A (0.53) HIF1ATSHRMEN1KMT2ANPC1
SCHEMBL10044898 0.82 HDAC4 (0.58) HDAC4HIF1ATSHRMEN1KMT2A
SCHEMBL11983226 0.81 EGFR (0.56) HDAC4HIF1ATSHRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1960363-B1 QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS AND USES THEREOF AMGEN INC (US) 2014-01-22 EP claimed
US-7728130-B2 Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity AMGEN INC. (US) 2010-06-01 US claimed
EP-1960363-B1 QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS AND USES THEREOF AMGEN INC (US) 2014-01-22 EP disclosed
US-8017626-B2 Quinolone based compounds exhibiting, prolyl hydroxylase inhibitory activity, and compositions, and uses thereof AMGEN INC. (US) 2011-09-13 US disclosed
US-8017626-B2 Quinolone based compounds exhibiting, prolyl hydroxylase inhibitory activity, and compositions, and uses thereof AMGEN INC. (US) 2011-09-13 US disclosed
US-8017626-B2 Quinolone based compounds exhibiting, prolyl hydroxylase inhibitory activity, and compositions, and uses thereof AMGEN INC. (US) 2011-09-13 US disclosed
US-8012968-B2 Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof AMGEN INC. (US) 2011-09-06 US disclosed
US-8012968-B2 Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof AMGEN INC. (US) 2011-09-06 US disclosed
US-8012968-B2 Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof AMGEN INC. (US) 2011-09-06 US disclosed
US-20100240610-A1 QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF AMGEN INC. 2010-09-23 US disclosed
US-20100240610-A1 QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF AMGEN INC. 2010-09-23 US disclosed
US-20100184763-A1 QUINOLONE BASED COMPOUNDS EXHIBITING, PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF AMGEN INC. 2010-07-22 US disclosed
US-20100184763-A1 QUINOLONE BASED COMPOUNDS EXHIBITING, PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF AMGEN INC. 2010-07-22 US disclosed
US-20100184763-A1 QUINOLONE BASED COMPOUNDS EXHIBITING, PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF AMGEN INC. 2010-07-22 US disclosed
US-7728130-B2 Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity AMGEN INC. (US) 2010-06-01 US disclosed
US-7728130-B2 Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity AMGEN INC. (US) 2010-06-01 US disclosed
US-7728130-B2 Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity AMGEN INC. (US) 2010-06-01 US disclosed
US-20070249605-A1 Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof AMGEN INC. 2007-10-25 US disclosed
US-20070249605-A1 Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof AMGEN INC. 2007-10-25 US disclosed
US-20070249605-A1 Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof AMGEN INC. 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100184763-A1 QUINOLONE BASED COMPOUNDS EXHIBITING, PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF EGLN3, HIF1AN, EGLN2 HDAC4 821/4885HIF1A 4/4885TSHR 4604/4885
US-20100240610-A1 QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF EGLN3, HIF1AN, EGLN2 HDAC4 743/4885HIF1A 4/4885TSHR 4541/4885
US-20070249605-A1 Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof EGLN3, HIF1AN, EGLN2 HDAC4 743/4885HIF1A 4/4885TSHR 4541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.